Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Eiichi Ogawa Last modified date:2024.03.18

Assistant Professor / Department of Environmental Medicine and Infectious Disease / Department of Clinical Medicine / Faculty of Medical Sciences


Papers
1. Jang TY, Liang PC, Jun DW, Jung JH, Toyoda H, Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon EL, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino I E, Abe H, Takahashi H, Inoue K, Yeh ML, Dai CY, Huang JF, Huang CF, Chuang WL, Nguyen MH, Yu ML., Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study, Journal of Gastroenterology and Hepatology, doi: 10.1111/jgh.16537, 2024.03.
2. Huang DQ, Hoang JK, Kamal R, Tsai PC, Toyoda H, Yeh ML, Yasuda S, Leong J, Maeda M, Huang CF, Won Jun D, Ishigami M, Tanaka Y, Uojima H, Ogawa E, Abe H, Hsu YC, Tseng CH, Alsudaney M, Yang JD, Yoshimaru Y, Suzuki T, Liu JK, Landis C, Dai CY, Huang JF, Chuang WL, Schwartz M, Dan YY, Esquivel C, Bonham A, Yu ML, Nguyen MH, Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma, Journal of Clinical Oncology, doi: 10.1200/JCO.23.00757, 42, 7, 790-799, 2024.03.
3. Park JE, Nguyen VH, Tsai PC, Toyoda H, Leong J, Guy JE, Yeh ML, Huang CF, Yasuda S, Abe H, Hsu YC, Tseng CH, Liu J, Chen YL, Lin PY, Jun DW, Yoshimaru Y, Ogawa E, Ishigami M, Enomoto M, Tamori A, Uojima H, Wang XZ, Xu Q, Takahashi H, Eguchi Y, Inoue K, Huang DQ, Zhao WJ, Chuang WL, Dai CY, Huang JF, Barnett S, Maeda M, Cheung R, Landis C, Tanaka Y, Roberts LR, Schwartz ME, Kumada T, Yu ML, Nguyen MH, Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response, Alimentary Pharmacology and Therapeutics, doi: 10.1111/apt.17863, 59, 6, 742-751, 2024.03.
4. Jang TY, Liang PC, Jun DW, Jung JH, Toyoda H, Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon EL, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino E, Abe H, Takahashi H, Inoue K, Huang JF, Chuang WL, Yeh ML, Dai CY, Huang CF, Nguyen MH, Yu ML., Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs, Kaohsiung Journal of Medical Sciences, doi: 10.1002/kjm2.12771, 40, 2, 188-197, 2024.02.
5. Ogawa E, Jun DW, Toyoda H, Hsu YC, Yoon EL, Ahn SB, Yeh ML, Do S, Trinh HN, Takahashi H, Enomoto M, Kawada N, Yasuda S, Tseng CH, Kawashima K, Lee HA, Inoue K, Haga H, Do AT, Maeda M, Hoang JH, Cheung R, Ueno Y, Eguchi Y, Furusyo N, Yu ML, Tanaka Y, Nguyen MH., Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study, Alimentary Pharmacology and Therapeutics, 59, 2, 239-248, 2024.01.
6. Wong YJ, Tran S, Huang CF, Hsu YC, Preda C, Toyoda H, Liu J, Jun DW, Landis C, Huang DQ, Gila A, Negoita L, Yasuda S, Tseng CH, Tsai PC, Uojima H, Nozaki A, Chuma M, Atsukawa M, Ishigami M, Itokawa N, Iio E, Lam CP, Watanabe T, Asai A, Yokohama K, Abe H, Enomoto M, Kawada N, Tamori A, Lee DH, Jun MJ, Do S, Vo DKH, Liu L, Li J, Ji F, Wang W, Li Y, Wang X, Guo F, Xu Q, Jing L, Ye Q, Pan H, Zhang J, Wen X, Wang Q, Ren H, Cai D, Shang J, Liu J, Lu C, Zang W, Li J, Niu J, Zhang M, Wu C, Huang R, Maeda M, Nakanishi A, Yeh ML, Chuang WL, Huang JF, Dai C, Ishikawa T, Takaguchi K, Senoh T, Trinh HN, Takahashi H, Eguchi Y, Quek SXZ, Haga H, Ogawa E, Wong G, Buti M, Fukunishi S, Ueno Y, Yuen MF, Tanaka Y, Lim SG, Cheung R, Yu ML, Nguyen MH, Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study, Hepatology International, doi:10.1007/s12072-023-10547-4, 17, 5, 1150-1161, 2023.10.
7. Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SX, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML, Nguyen MH, Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase, Hepatology, doi:10.1097/HEP.0000000000000459, 78, 5, 1558-1568, 2023.11.
8. Nguyen VH, Huang DQ, Le MH, Jin M, Lee EY, Henry L, Nerurkar SN, Ogawa E, Thin KN, Teng MLP, Goh KS, Kai JCY, Wong C, Tan DJH, Thuy LTT, Hai H, Enomoto M, Cheung R, Nguyen MH, Global treatment rate and barriers to direct-acting antiviral therapy: A systematic review and meta-analysis of 146 studies and 1 760 352 hepatitis C virus patients, Liver International, doi:10.1111/liv.15550, 43, 6, 1195-1203, 2023.06.
9. Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, Cheung R, Nguyen MH, Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C, JAMA Internal Medicine, doi:10.1001/jamainternmed.2022.5699, 183, 2, 97-105, 2023.02.
10. Kimura M, Ogawa E, Harada K, Imamura J, Saio M, Ikura Y, Yatsuhashi H, Murata K, Miura K, Ieiri I, Tanaka A, Kimura K, Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study, BMJ Open Gastroenterology, doi: 10.1136/bmjgast-2022-001001, 9, 1, e001001, 2022.11.
11. Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J, Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: Week 144 results from a real-world, multicentre cohort study, Alimentary Pharmacology and Therapeutics, doi:10.1111/apt.17107, 56, 4, 713-722, 2022.08.
12. Ohta A, Ogawa E, Murata M, Matsumoto Y, Yamasaki S, Ikezaki H, Furusyo N, Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication, Journal of Medical Virology, 10.1002/jmv.27904, 2022.06.
13. Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T, Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study, EBioMedicine, 10.1016/j.ebiom.2022.104069, 80, 104069, 2022.06.
14. Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J, Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study, Hepatology International, doi:10.1007/s12072-021-10295-3, 16, 2, 282-293, 2022.04.
15. Huang CF, Tyng-Yuan J, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, Yu ML, On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, Liver International, doi: 10.1111/liv.15085, 42, 1, 59-68, 2022.01.
16. Ogawa E, Kawano A, Ooho A, Furusyo N, Satoh T, Takahashi K, Kajiwara E, Dohmen K, Nakamuta M, Azuma K, Koyanagi T, Yamashita N, Yanagita K, Ichiki Y, Kuniyoshi M, Yamashita N, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J, Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection, Journal of Gastroenterology and Hepatology, doi: 10.1111/jgh.15703, 37, 2, 371-377, 2022.02.
17. Mak LY, Hoang J, Jun DW, Chen CH, Peng CY, Yeh ML, Kim SE, Huang DQ, Jeong JY, Yoon E, Oh H, Tsai PC, Huang CF, Ahn SB, Trinh H, Xie Q, Wong GLH, Enomoto M, Shim JJ, Lee DH, Liu L, Kozuka R, Cho YK, Jeong SW, Kim HS, Trinh L, Dao A, Huang R, Hui RW, Tsui V, Quek S, Khine HHTW, Ogawa E, Dai CY, Huang JF, Cheung R, Wu C, Chuang WL, Lim SG, Yu ML, Yuen MF, Nguyen MH, Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study, Hepatology International, 10.1007/s12072-021-10271-x, 16, 1, 48-58, 2022.02.
18. Ogawa E, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Yamashita N, Ichiki Y, Yamashita N, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J, Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals, Journal of Gastroenterology and Hepatology, doi: 10.1111/jgh.15659, 37, 1, 190-199, 2022.01.
19. Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH, Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine, Clinical Gastroenterology and Hepatology, doi: 10.1016/j.cgh.2021.05.062, 20, 4, 874-885, 2022.04.
20. Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, Arai T, Fukunishi S, Ogawa E, Hsu YC, Maeda M, Dang H, Tseng CH, Takahashi H, Jun DW, Watanabe T, Chuma M, Nozaki A, Kawada N, Cheung R, Enomoto M, Takaguchi K, Toyoda H, Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir, American Journal of Gastroenterology, 116, 6, 1264-1273, 2021.06.
21. Ikezaki H, Furusyo N, Nakashima R, Umemoto M, Yamamoto K, Matsumoto Y, Ohta A, Yamasaki S, Hiramine S, Takayama K, Ogawa E, Toyoda K, Murata M, Shimono N, Hayashi J, Kyushu and Okinawa Population Study (KOPS): a large prospective cohort study in Japan, BMJ Open, 10.1136/bmjopen-2021-053763, 11, 12, e053763, 2021.12.
22. Yeh ML, Liang PC, Tsai PC, Wang SC, Leong J, Ogawa E, Jun DW, Tseng CH, Landis C, Tanaka Y, Huang CF, Hayashi J, Hsu YC, Huang JF, Dai CY, Chuang WL, Nguyen MH, Yu ML, Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR, Cancers, 13, 14, 3455, 2021.07.
23. Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M, Maeda M, Thin KN, Tanaka K, Takahashi Y, Itoh Y, Oniki K, Seko Y, Saruwatari J, Kawanaka M, Atsukawa M, Hyogo H, Ono M, Ogawa E, Barnett SD, Stave CD, Cheung RC, Fujishiro M, Eguchi Y, Toyoda H, Nguyen MH, The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040, Hepatology International, 15, 2, 366-379, 2021.04.
24. Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung M, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH, Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients, Hepatology International, 15, 1, 71-81, 2021.02.
25. Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH, Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B, American Journal of Gastroenterology, 115, 2, 271-280, 2020.02.
26. Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH, Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West, Hepatology, 71, 6, 1910-1922, 2021.06.
27. Tanaka Y, Ogawa E, Huang CF, Toyoda H, Jun DW, Tseng CH, Hsu YC, Enomoto M, Takahashi H, Furusyo N, Yeh ML, Iio E, Yasuda S, Lam CP, Lee DH, Haga H, Yoon EL, Ahn SB, Wong G, Nakamuta M, Nomura H, Tsai PC, Jung JH, Song DS, Dang H, Maeda M, Henry L, Cheung R, Yuen MF, Ueno Y, Eguchi Y, Tamori A, Yu ML, Hayashi J, Nguyen MH, HCC risk post-SVR with DAAs in East Asians: Finding from the REAL-C cohort, Hepatology International, 2020.12.
28. Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J, Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C, Cancers, 12, 9, E2602, 2020.09.
29. Ogawa E, Takayama K, Hiramine S, Hayashi T, Toyoda K, Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination, Alimentary Pharmacology and Therapeutics, 52, 5, 866-876, 2020.09.
30. Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J, Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals, The Journal of Infectious Disease, doi:org/10.1093/infdis/jiaa359, 226, 3, 431-440, 2022.08.
31. Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, Takahashi K, Azuma K, Kato M, Shimoda S, Hayashi J, Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B, Liver International, 40, 7, 1578-1589, 2020.07.
32. Eiichi Ogawa, Yee Hui Yeo, Nolan Dang, Michael H. Le, Donghak Jeong, Sally Tran, Linda Henry, Ramsey Cheung, Mindie H. Nguyen, Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States, JAMA Network Open, 3, 4, e201844, 2020.04.
33. Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jung Jun M, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH, HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication, Clinical Infectious Diseases, 71, 11, 2840-2848, 2020.12.
34. Ogawa E, Nomura H, Nakamuta M, Kawano A, Dohmen K, Kajiwara E, Satoh T, Koyanagi T, Takahashi K, Ooho A, Azuma K, Furusyo N, Kato M, Shimoda S, Hayashi J, Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis, Hepatology Research, 50, 2, 174-181, 2020.02.
35. Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH, Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis, Journal of Hepatology, 71, 3, 473-485, 2019.09.
36. Mitsumoto-Kaseida F, Murata M, Takayama K, Toyoda K, Ogawa E, Furusyo N, Hayashi J, Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients, Journal of Infection and Chemotherapy , 10.1016/j.jiac.2019.06.003, 26, 1, 28-32, 2020.01.
37. Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH, REAL-B risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy, The Journal of Infectious Diseases, 221, 3, 389-399, 2020.01.
38. Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH, Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium, Hepatology International, 13, 5, 587-598, 2019.09.
39. Igarashi A, Furusyo N, Ogawa E, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J, Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan, BMJ Open, 9, 6, e023405, 2019.06.
40. Ogawa E, Furusyo N, Nakamuta M, Nomura H, Satoh T, Takahashi K, Koyanagi T, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Kato M, Shimoda S, Hayashi J, Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study, Hepatology Research, 10.1111/hepr.13328, 49, 6, 617-626, 2019.06.
41. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH, Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis, The Lancet Gastroenterology & Hepatology, 10.1016/S2468-1253(19)30039-1, 4, 5, 389-398, 2019.03.
42. Eiichi Ogawa, Norihiro Furusyo, Koichi Azuma, Makoto Nakamuta, Hideyuki Nomura, Kazufumi Dohmen, Takeaki Satoh, Akira Kawano, Toshimasa Koyanagi, Aritsune Ooho, Kazuhiro Takahashi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Elbasvir plus Grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease, Antiviral Research, 10.1016/j.antiviral.2018.10.003, 159, 143-152, 2018.11.
43. Wei B, Ji F, Yeo YH, Ogawa E, Stave CD, Dang S, Li Z, Furusyo N, Cheung RC, Nguyen MH, Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia, BMJ Open Gastroenterology, 10.1136/bmjgast-2018-000209, 5, 1, e000209, 2018.08.
44. Wei B, Ji F, Yeo YH, Ogawa E, Zou B, Stave CD, Dang S, Li Z, Furusyo N, Cheung RC, Nguyen MH, Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis, BMJ Open Gastroenterology, 10.1136/bmjgast-2018-000207, 5, 1, e000207, 2018.06.
45. Ji F, Wei B, Yeo YH, Ogawa E, Zou B, Stave CD, Li Z, Dang S, Furusyo N, Cheung RC, Nguyen MH, Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia, Alimentary Pharmacology & Therapeutics, 10.1111/apt.14507, 47, 5, 550-562, 2018.03.
46. Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J, Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 10.1111/apt.14380, 47, 1, 104-113, 2018.01.
47. Ogawa E, Furusyo N, Murata M, Toyoda K, Hayashi T, Ura K, Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV, LIVER INTERNATIONAL, 10.1111/liv.13496, 38, 1, 76-83, 2018.01.
48. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b, Journal of Gastroenterology, 52, 7, 845-854, 2017.07.
49. Eiichi Ogawa, Norihiro Furusyo, Masayuki Murata, Motohiro Shimizu, Toyoda Kazuhiro, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy, Antiviral Therapy, 10.3851/IMP3085, 22, 1, 61-70, 2017.03.
50. Eiichi Ogawa, Norihiro Furusyo, Naoki Yamashita, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Makoto Nakamuta, Takeaki Satoh, Hideyuki Nomura, Koichi Azuma, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis, Hepatology Research, doi: 10.1111/hepr.12738, 47, 3, E120-E131, 2017.03.
51. Mitsumoto-Kaseida Fujiko, Masayuki Murata, Kazuya Ura, Koji Takayama, Satoshi Hiramine, Toyoda K, Eiichi Ogawa, Norihiro Furusyo, The Expression Level of Neutrophil CD64 Is a Useful Marker of Systemic Inflammation Associated with HIV Infection, AIDS research and human retroviruses, 33, 2, 147-156, 2017.02.
52. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazuhiro Takahashi, Nobuhiko Higashi, Akira Kawano, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis, Antiviral Research, 24, 136, 37-44, 2016.12.
53. Motohiro Shimizu, Norihiro Furusyo, Yuuki Tanaka, Yoshifumi Kato, Mitsumoto-Kaseida Fujiko, Koji Takayama, Kazuya Ura, Satoshi Hiramine, Takeo Hayashi, Hiroaki Ikezaki, Takeshi Ihara, Haru Mukae, Eiichi Ogawa, Toyoda Kazuhiro, Masayuki Murata, Jun Hayashi, The relation of postprandial plasma glucose and serum endostatin to the urinary albumin excretion of residents with prediabetes: results from the Kyushu and Okinawa Population Study (KOPS), International Urology and Nephrology, 48, 6, 851-857, 2016.06.
54. Hiroaki Ikezaki, Norihiro Furusyo, Satoshi Hiramine, Kazuya Ura, Fujiko Kaseida, Koji Takayama, Motohiro Shimizu, Kazuhiro Toyoda, Eiichi Ogawa, Mosaburo Kainuma, Murata Masayuki, Jun Hayashi, Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study, Archives of Virology, 161, 3, 641-648, 2016.03.
55. Hiroaki Ikezaki, Hideyuki Nomura, Norihiro Furusyo, Eiichi Ogawa, Eiji Kajiwara, Kazuhiro Takahashi, Akira Kawano, Toshihiro Maruyama, Yuji Tanabe, Takeaki Satoh, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi, Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C, Hepatology Research, 46, 3, 174-180, 2016.03.
56. Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Takeo Hayashi, Motohiro Shimizu, Haru Mukae, Kazuhiro Toyoda, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy, Antiviral Research, 126, 35-42, 2016.02.
57. Takeo Hayashi, Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Jun Hayashi, Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C, Infectious agents and cancer, 24, 11, 9, 2016.02.
58. Kazuya Ura, Norihiro Furusyo, Eiichi Ogawa, Takeo Hayashi, Haru Mukae, Motohiro Shimizu, Kazuhiro Toyoda, Murata Masayuki, Jun Hayashi, Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C, Alimentary Pharmacology and Therapeutics, 43, 1, 114-124, 2016.01.
59. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection, Journal of Gastroenterology and Hepatology, 30, 12, 1759-1767, 2015.12.
60. Eiichi Ogawa, Norihiro Furusyo, Kazufumi Dohmen, Eiji Kajiwara, Akira Kawano, Hideyuki Nomura, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure, Journal of Viral Hepatitis, 22, 12, 992-1001, 2015.12.
61. Satoshi Hiramine, Norihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C, World Journal of Hepatology, 7, 26, 2688-2695, 2015.11.
62. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Comparative safety study on severe anemia by simeprevir- versus telaprevir-based triple therapy for chronic hepatitis C, Journal of Gastroenterology and Hepatology, doi: 10.1111/jgh.12945., 30, 8, 1309-1316, 2015.08.
63. Akira Kawano, Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Kazufumi Dohmen, Hideyuki Nomura, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Yuichi Tanabe, Shinji Shimoda, Kazuhiro Kotoh, Jun Hayashi, Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection, Internal Medicine, 54, 6, 567-572, 2015.06.
64. Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Murata Masayuki, Jun Hayashi, Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients, World Journal of Gastroenterology, 21, 15, 4696-4706, 2015.04.
65. Mitsumoto F, Murata M, Ura K, Takayama K, Hiramine S, Shimizu M, Toyoda K, Ogawa E, Furusyo N, Hayashi J, The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients, Journal of Infection and Chemotherapy, 10.1016/j.jiac.2014.12.003, 21, 4, 264-271, 2015.04.
66. Motohiro Shimizu, Norihiro Furusyo, Fujiko Mitsumoto, Koji Takayama, Kazuya Ura, Satoshi Hiramine, Hiroaki Ikezaki, Takeshi Ihara, Haru Mukae, Eiichi Ogawa, Kazuhiro Toyoda, Mosaburo Kainuma, Murata Masayuki, Jun Hayashi, Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS), Atherosclerosis, 238, 2, 207-212, 2015.02.
67. Shimizu M, Furusyo N, Ikezaki H, Ogawa E, Hayashi T, Ihara T, Harada Y, Toyoda K, Murata M, Hayashi J, Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B, World Journal of Gastroenterology, 10.3748/wjg.v21.i7.2116, 21, 7, 2116-2212, 2015.02.
68. Mosaburo Kainuma, Norihiro Furusyo, Shinichi Ando, Haru Mukae, Eiichi Ogawa, Kazuhiro Toyoda, Murata Masayuki, Jun Hayashi, Nocturnal difference in the ultra low frequency band of heart rate variability in patients stratified by Kampo medicine prescription, Circulation Journal, 78, 8, 1924-1927, 2014.07.
69. Eiichi Ogawa, Norihiro Furusyo, Motohiro Shimizu, Takeshi Ihara, Takeo Hayashi, Yuji Harada, Kazuhiro Toyoda, Murata Masayuki, Jun Hayashi, Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C, ANTIVIRAL THERAPY, 20, 185-192, 2015.05.
70. Norihiro Furusyo, Eiichi Ogawa, Murata Masayuki, Kazuhiro Toyoda, Hachiro Ohnishi, Kunimitsu Eiraku, Motohiro Shimizu, Fujiko Mitsumoto, Koji Takayama, Mosaburo Kainuma, Okada Kyoko, Jun Hayashi, Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response, JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 10.1093/jac/dkt371, 69, 2, 483-490, 2014.02.
71. Ikezaki H, Furusyo N, Ogawa E, Shimizu M, Hiramine S, Ura K, Mitsumoto F, Takayama K, Toyoda K, Murata M, Hayashi J, Efficacy and tolerance of interferon β plus ribavirin treatment for chronic hepatitis C patients with depression and thrombocytopenia: Comparison with pegylated interferon α plus ribavirin treatment, Journal of Liver, 3, 155, 2014.03.
72. Furusyo N, Ikezaki H, Hayashi T, Ihara T, Hiramine S, Mitsumoto F, Ura K, Takayama K, Toyoda T, Ogawa E, Kainuma M, Murata M, Hayashi J, The association between serum undercarboxylated osteocalcin level and type-2 diabetes mellitus: Results from the Kyushu and Okinawa Population Study, Journal Clinical Research and Drug Development, 2, 2014.01.
73. Hiroaki Ikezaki, Norihiro Furusyo, Kyoko Okada, Takeshi Ihara, Takeo Hayashi, Eiichi Ogawa, Mosaburo Kainuma, Murata Masayuki, Jun Hayashi, The utility of urinary myo-inositol as a marker of glucose intolerance, DIABETES RESEARCH AND CLINICAL PRACTICE, 10.1016/j.diabres.2013.11.018, 103, 1, 88-96, 2014.01.
74. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Tomohiko Akahoshi, Yoshihiko Maehara, Jun Hayashi, Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis, Journal of Gastroenterology and Hepatology, 29, 1728-1735, 2014.09.
75. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Makoto Nakamuta, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection, Antiviral Research, 104, 102-109, 2014.04.
76. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: A prospective clinical study , Alimentary Pharmacology and Therapeutics, 38, 9, 1076-1085, 2013.11.
77. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy, Journal of Hepatology, 59, 4, 667-674, 2013.09.
78. Ahmed WH, Furusyo N, Zaky S, Eldin AS, Aboalam H, Ogawa E, Murata M, Hayashi J, Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients, World Journal of Gastroenterology, 19, 9, 1387-1395, 2013.03.
79. Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Kazuhiro Toyoda, Kunimitsu Eiraku, Motohiro Shimizu, Yuji Harada, Fujiko Mitsumoto, Koji Takayama, Okada Kyoko, Mosaburo Kainuma, Jun Hayashi, Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays, Antiviral Research, 99, 2, 119-124, 2013.08.
80. Norihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C, Journal of Hepatology, 59, 2, 205-212, 2013.08.
81. Shimoda S, Sumida K, Iwasaka S, Hisamoto S, Tanimoto H, Nomura H, Dohmen K, Takahashi K, Kawano A, Ogawa E, Furusyo N, Akashi K, Hayashi J, Interferon- α -Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections, Hepatitis Research and Treatment, 10.1155/2013/374196, 2013, 374196, 2013.08.
82. Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Hiroaki Ikezaki, Takeshi Ihara, Takeo Hayashi, Kazuhiro Toyoda, Okada Kyoko, Mosaburo Kainuma, Eiji Kajiwara, Kazuhiro Takahashi, Takeaki Satoh, Jun Hayashi, Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia, Journal of Viral Hepatitis, 20, 12, 838-846, 2013.12.
83. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Toshihiro Maruyama, Yuichi Tanabe, Takeaki Satoh, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi, Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: A prospective, multicenter study, Journal of Hepatology, 58, 3, 495-501, 2013.03.
84. Kainuma M, Furusyo N, Murata M, Ihara T, Ikezaki H, Toyoda K, Ogawa E, Okada K, Hayashi J, The effectiveness of traditional Japanese medicine (Kampo) in combination with pegylated interferon α plus ribavirin for patients with chronic hepatitis C: A pilot study, Journal of Traditional Medicine, 30, 3, 132-139, 2013.03.
85. Furusyo N, Ihara T, Hayashi T, Ikezaki H, Toyoda K, Ogawa E, Okada K, Kainuma M, Murata M, Hayashi J, The serum undercarboxylated osteocalcin level and the diet of a Japanese population: results from the Kyushu and Okinawa Population Study (KOPS), Endocrine, 43, 3, 635-642, 2013.01.
86. Norihiro Furusyo, Eiichi Ogawa, Masayuki Sudoh, Murata Masayuki, Takeshi Ihara, Takeo Hayashi, Hiroaki Ikezaki, Satoshi Hiramine, Haru Mukae, Kazuhiro Toyoda, Okada Kyoko, Mosaburo Kainuma, Eiji Kajiwara, Jun Hayashi, Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: A randomized trial, Journal of Hepatology, 57, 6, 1186-1192, 2012.12.
87. Okada K, Furusyo N, Ogawa E, Ikezaki H, Ihara T, Hayashi T, Kainuma M, Murata M, Hayashi J, Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide, Endocrine, 43, 1, 200-205, 2013.02.
88. Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J, Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1, Journal of Hepatology, 57, 3, 534-540, 2012.09.
89. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi, An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin., Journal of Infection and Chemotherapy, DOI: 10.1007/s10156-012-0396-5, 18, 5, 689-697, 2012.10.
90. Furusyo N, Walaa AH, Eiraku K, Toyoda K, Ogawa E, Ikezaki H, Ihara T, Hayashi T, Kainuma M, Murata M, Hayashi J., Treatment for Eradication of Helicobacter pylori Infection among Chronic Hepatitis C Patients., Gut Liver, 5, 4, 447-453, 2011.12.
91. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group., An evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study (KULDS), Journal of Gastroenterology and Hepatology, 27, 7, 1233-1240, 2012.07.
92. Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J., Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients., World Journal of Gastroenterology, 17, 24, 2945-2952, 2011.06.
93. Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, Ihara T, Ikezaki H, Hayashi T, Kainuma M, Hayashi J., Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog, Hepatology Research, 41, 12, 1178-88, 2011.12.
94. Ikezaki H, Furusyo N, Ihara T, Hayashi T, Ogawa E, Toyoda K, Taniai H, Kainuma M, Murata M, Hayashi J, Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C, Journal of Infection and Chemotherapy, 17, 6, 737-743, 2011.12.
95. Ogawa E, Furusyo N, Toyoda K, Taniai H, Otaguro S, Kainuma M, Murata M, Sawayama Y, Hayashi J., Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b and ribavirin treatment., BMC Gastroenterology, 10, 38, 2010.04.
96. Furusyo N, Murata M, Ogawa E, Toyoda K, Ihara T, Ikezaki H, Hayashi T, Koga T, Kainuma M, Hayashi J., Ribavirin concentration in the later stages of 48-week pegylated interferon-alfa 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response., Journal of Antimicrobial Chemotherapy, 66, 5, 1127-1139, 2011.05.
97. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J., The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients with treated with pegylated interferon alpha-2b and ribavirin., Antiviral Research, 83, 2, 127-134, 2009.04.
98. Murata M, Furusyo N, Fujimoto Y, Kanamoto-Tanaka Y, Otaguro S, Ogawa E, Yasuhara T, Yamamoto N, Hayashi J, Evaluation of a new desktop washer-disinfector for the viral disinfection of medical devices, Japanese Society of Environmental Infections, 22, 2, 118-121, 2007.02.
99. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Otaguro S, Hamada M, Murata M, Sawayama Y, Hayashi J., Transient elastography for patients with chronic hepatitis B and C virus infection: A noninvasive, quantitative assessment of liver fibrosis., Hepatology Research, 37, 12, 1002-1010, 2007.12.